Anthony Letai, Director of the National Cancer Institute, shared on X:
“Small-cell lung cancer has been one of the hardest cancers to treat.
A practice-changing phase 3 trial reported in NEJM found that adding the T-cell engager tarlatamab to maintenance durvalumab extended median survival from about a year to nearly two.”
You can also read:
